Related Experiment Video
Updated: Jun 14, 2025
14:24
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
11.6K
Management of Cancer Therapy-Related Cardiac Dysfunction: A Case-Based Review
Jaya Mallidi1, Richard Baylis2, Evelyn J Song2
1Division of Cardiology, Department of Medicine, Zuckerberg San Francisco General Hospital; Division of Cardiology, Department of Medicine, University of California San Francisco, San Francisco, California.
The American Journal of Cardiology
|September 5, 2024
Summary
Cardiologists must manage cancer therapy-related cardiac dysfunction, from mild left ventricular issues to heart failure. Early diagnosis and a team approach are key for patients receiving treatments like anthracyclines, HER2-targeted therapies, and immune checkpoint inhibitors.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Cancer therapies increasingly cause cardiac dysfunction.
- This dysfunction ranges from asymptomatic to severe heart failure.
- Management requires collaboration between oncologists and cardiologists.
Purpose of the Study:
- Provide a practical guide for clinicians.
- Focus on diagnosis and management of cardiac dysfunction.
- Cover common cancer treatments: anthracyclines, HER2-targeted therapies, and immune checkpoint inhibitors.
Main Methods:
- Case-based review.
- Clinical practice guidance.
- Literature synthesis on cardiotoxicity.
Main Results:
- Cancer therapies pose significant cardiac risks.
- Early detection of cardiac dysfunction is crucial.
- Tailored management strategies are essential for different therapies.
Conclusions:
- Multidisciplinary care improves outcomes for patients with cancer therapy-related cardiac dysfunction.
- Clinicians need awareness of specific drug toxicities.
- Proactive cardiac monitoring and management are vital.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:22Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:17Increased pulse rate
651
Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
651
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K